Match tier
Likely match
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-08
S
Stefan Longobardi
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Graduate Student Researcher
2 pubs
Research Areas
Biography and Research Information
OverviewAI-generated summary
Stefan Longobardi's research focuses on multiple myeloma, specifically investigating therapeutic approaches and patient outcomes. He has co-authored publications exploring the influence of genomic and clinical high-risk features on the effectiveness of bispecific antibody therapy in relapsed/refractory multiple myeloma. His work also delves into the insights and future directions of G protein-coupled receptor class C group 5 member D (GPRC5D) therapies for multiple myeloma. Longobardi collaborates with researchers at the University of Arkansas for Medical Sciences, including Shoon Lei Oo, Carolina Schinke, Maurizio Zangari, and Frits van Rhee, contributing to a shared publication record in this area.
Metrics
- Publications: 2
Selected Publications
-
Insights and Future Directions of GPRC5D Therapies in Multiple Myeloma (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
Collaboration Network
Top Collaborators
Shoon Lei Oo
University of Arkansas for Medical Sciences
2 shared publications
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
- Insights and Future Directions of GPRC5D Therapies in Multiple Myeloma
Asis Shrestha
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Anup Kumar Trikannad
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Sruthi Vellanki
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Hira Imad Cheema
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Sanjay Muttineni
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Syed Naqvi
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Anushareddy Muddasani
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Sasya Dronavalli
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Samer Al Hadidi
Southwestern Medical Center (US)
1 shared publication
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Maurizio Zangari
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Frits van Rhee
Winthrop Rockefeller Foundation
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Niels Weinhold
Heidelberg University (DE)
1 shared publication
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Carolina D. Schinke
University of Arkansas for Medical Sciences
1 shared publication
In database
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Similar Researchers
Based on overlapping research topics
Asis Shrestha
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Genomics and Phylogenetic Studies
Mary Price
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Monoclonal and Polyclonal Antibodies Research
Divaya Bhutani
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Retrospective Studies
Anup Kumar Trikannad
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Retrospective Studies
Hira Imad Cheema
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Retrospective Studies
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Monoclonal and Polyclonal Antibodies Research